Printer Friendly
The Free Library
4,488,600 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.


Tokyo, Japan, Aug 26, 2005 - (JCN JCN - Jane's Combat Network
JCN - Japan Corporate News
JCN - Jewish Congregational Network
JCN - Job Control Number
JCN - joint communications network (US DoD)
JCN - Journal of Cardiovascular Nursing
JCN - Journal of Child Neurology
JCN - Journal of Christian Nursing
JCN - Journal of Cognitive Neuroscience neu·ro·sci·ence (nr-s
JCN - Journal on Communications Networks (IEEE Communications Society)
 Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and BioArctic Neuroscience Inc. (Headquarter: Uppsala Uppsala (ŭp`sələ, –sä'lä), city (1990 pop. 109,500), capital of Uppsala co., E Sweden, on the Fyrisån River. It is an industrial and cultural center and a railroad junction. Manufactures include machinery, printed materials, processed food, clothing, pharmaceuticals, and footwear., Sweden, CEO: Par Gellerfors) announced today that on August 24, they signed a strategic alliance agreement to develop an immunotherapy immu·no·thera·peutic (-py for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia.. Based on this agreement, Eisai will obtain first right of refusal for drug candidates developed resulting from the research.

BioArctic Neuroscience Inc. is a biotech company that was established in January, 2003, with the aim of industrial application of Alzheimer's disease research by Prof. Lannfelt, Uppsala University, who is an internationally well-known Alzheimer's disease researcher.

Currently, Prof. Lannfelt's group is conducting basic research to further advance knowledge about the Arctic mutation of A, for immunotherapy in Alzheimer's disease. Arctic mutation of A is a mutation discovered by Prof. Lannfelt in 2001. It causes familial Alzheimer's disease and pathophysiologically shows very similar lesions to those found in non-familial Alzheimer's disease familial Alzheimer's disease
n.
An inherited form of Alzheimer's disease caused by a defect on a particular chromosome.
. In this respect, Arctic mutation of Ais expected to be applied to evaluate efficacy in a wide range of Alzheimer's disease treatment. The research will be carried out mainly by BioArctic Neuroscience and Prof. Lannfelt.

Eisai actively puruses Purus (prz`), river, c.2,100 mi (3,380 km) long, rising in the Andes Mts., E Peru. It flows generally northeast in a meandering course, across Acre and Amazonas states, NW Brazil, to the Amazon River. alliances with outside organizations in order to expand its product line-up in the neurology arena, one of the company's franchise areas. With the BioArctic Neuroscience agreement, Eisai wishes to gain a new immunotherapy in drug treatment of Alzheimer's disease cut out by Aricept Ar·i·cept (âr-spt, and lead to a novel, beneficial treatment for Alzheimer's disease.

Contacts:

Copyright [c] 2005 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:9JAPA
Date:Aug 27, 2005
Words:264
Previous Article:Regarding a Fire at Sanix Energy Tomakomai Power Plant.
Next Article:Showa Denko K.K. (SDK) Starts Production of 32-Inch Graphite Electrodes.
Topics:



Related Articles
Brain goals for the 1990s. (Dana Alliance for Brain Initiatives identifies research goals to attain by 2000) (Brief Article)
Enzyme offers promise of Alzheimer's drugs.(beta-secretase)(Brief Article)
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Building bridges.(HEALTH CARE & BIOTECH)
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles